JohnRTeerlinkMD

Cardiology • San Francisco, CA

Professor, Medicine, UCSF School of Medicine; Director, Heart Failure and Director, Echocardiography, SFVAMC

Join to view full profile

Dr. Teerlink is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Teerlink's full profile

Already have an account?

Office
4150 Clement St
Sfvamc; Cardiology 111c
San Francisco, CA 94121
Phone+1 415-750-2112

Fax+1 415-750-6950

Education & Training

University of California (San Francisco)Fellowship, Cardiovascular Disease, 1991 - 1995
University of California (San Francisco)Residency, Internal Medicine, 1988 - 1991
Harvard Medical SchoolClass of 1988
Swarthmore CollegeBA, Religion/ Cell Biology, Highest Honors in Honors program, 1979 - 1983

Certifications & Licensure

CA State Medical License 1990 - 2025

Awards, Honors, & Recognition

Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

687 citations
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardio...
Biykem Bozkurt, Andrew J.S. Coats, Hiroyuki Tsutsui, Ca Magdy Abdelhamid, Stamatis Adamopoulos
European Journal of Heart Failure. 2021-03-01
151 citations
Effects of Serelaxin in Patients with Acute Heart Failure
Marco Metra, John R. Teerlink, Gad Cotter, Beth Davison, G. Michael Felker
The New England Journal of Medicine. 2019-08-21
24 citations
The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction
Alia Saed Alhakak, John R. Teerlink, JoAnn Lindenfeld, Michael Böhm, Giuseppe M.C. Rosano
European Journal of Heart Failure. 2021-02-15

Journal Articles

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
John R Teerlink, David E Lanfear, Thomas M Suter, Narimon Honarpour, Siddique A Abbasi, Fady I Malik, Christopher E Kurtz, The New England Journal of Medicine
Effect of Implantable Cardioverter-Defibrillators by Etiology of Heart Failure: A Propensity-Matched Mortality Analysis of the WARCEF Trial
John R Teerlink, Ronald S Freudenberger, Arthur J Labovitz, Shunichi Homma, Siqin Ye, Journal of Cardiac Failure
Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure
Javed Butler, John R Teerlink, Lukasz P Cerbin, Adam D DeVore, Randall C Starling, Adrian F Hernandez, Robert J Mentz, ScienceDirect
Agents with Vasodilator Properties in Acute Heart Failure
John Teerlink, MD, European Heart Journal
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): A Phase 2, Pharmacokinetic, Randomised, Placebo-Controlled Trial
G. Michael Felker, John R. Teerlink, The Lancet
Join now to see all

Lectures

Effect of Omecamtiv Mecarbil in Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction: Results From COSMIC-HF
2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
Hemodynamics in Heart Failure: Understanding the Fundamentals
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Drug Therapies in Acute Heart Failure: The Old and New, What Works and What Doesn't?
2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Exercise Capacity and Fatigue: Valid Surrogates in Heart Failure Trials?
2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Relaxin Reduces Dyspnea, Cardiovascular Death, and Rehospitalization in Acute Heart Failure
58th Annual Scientific Session & Expo, Orlando, Florida, USA
Relaxin Reduces Dyspnea, Cardiovascular Death, and Rehospitalization in Acute Heart Failure
American College of Cardiology, 58th Annual Scientific Session & Expo, Orlando, Florida, USA
Serelaxin as a Novel Treatment for Acute Heart Failure: Results of the RELAX-AHF Trial
American Heart Association, Scientific Sessions 2012, Los Angeles, California, USA
New Evidence: Treatment of Heart Failure
ESC Congress 2012, Munich, Germany
Omecamtiv Mecarbil: Phase 2 Study Shows No Improvement in Dyspnea AHF but Trend for Further Exploration
ESC Congress 2013, Amsterdam, The Netherlands
New Evidence: Treatment of Heart Failure
European Society of Cardiology, ESC Congress 2012, Munich, Germany
Omecamtiv Mecarbil: Phase 2 Study Shows No Improvement in Dyspnea AHF but Trend for Further Exploration
European Society of Cardiology, ESC Congress 2013, Amsterdam, The Netherlands
Serelaxin as a Novel Treatment for Acute Heart Failure: Results of the RELAX-AHF Trial
Scientific Sessions 2012, Los Angeles, California, USA
Join now to see all

Authored Content

Effect of Implantable Cardioverter-Defibrillators by Etiology of Heart Failure: A Propensity-Matched Mortality Analysis of the WARCEF TrialAugust 2018
Prevalence, Predictors and Clinical Outcome of Residual Congestion in Acute Decompensated Heart FailureMarch 2018
Prevalence, Predictors and Clinical Outcome of Residual Congestion in Acute Decompensated Heart FailureMarch 2018
Prevalence, Predictors and Clinical Outcome of Residual Congestion in Acute Decompensated Heart FailureMarch 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsMarch 2017
Join now to see all

Press Mentions

Does Finerenone's Efficacy Diminish if Initiated Late in Heart Failure?September 29th, 2024
Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional DataMay 30th, 2022
Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart Association Scientific Sessions 2021November 15th, 2021
Join now to see all